{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T18:21:33Z","timestamp":1769883693245,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","award":["2020B005"],"award-info":[{"award-number":["2020B005"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) are commonly inherited heart conditions associated with a\u00a0high risk of heart failure and sudden cardiac death. To understand the economic and societal disease burden, this study systematically identified and reviewed cost-of-illness (COI) studies and economic evaluations (EEs) of various interventions for HCM and DCM. A\u00a0literature search was performed in MEDLINE, EMBASE, NHS EED, EconLit and Web of Science to identify COI studies and EEs published between 1\u00a0January 2010 and 28\u00a0April 2021. The selection of studies and their critical appraisal were performed jointly by two independent researchers. For the quality assessment, the \u2018Consensus on Health Economic Criteria\u2019 list was used. Two COI studies and 11\u00a0EEs were eligible for inclusion. Cost-effectiveness varied among interventions and depended on the targeted patient population. Both COI studies identified only hospitalisation costs in HCM. The mean study quality was high in EEs but low in COI studies. Most studies excluded costs for patients, caregivers and productivity losses. Overall, knowledge of the societal and economic burden of inherited cardiomyopathies is limited. Future research needs to include quality-adjusted life years and a\u00a0broader range of costs to provide an information base for optimising care for affected patients.<\/jats:p>","DOI":"10.1007\/s12471-023-01776-1","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T12:02:12Z","timestamp":1683892932000},"page":"226-237","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A\u00a0systematic literature review of economic evaluations and cost-of-illness studies of inherited cardiomyopathies"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2608-2900","authenticated-orcid":false,"given":"Isabell","family":"Wiethoff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"Goversen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Michels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanda","family":"van der Velden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micka\u00ebl","family":"Hiligsmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Kugener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia M. A. A.","family":"Evers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"1776_CR1","doi-asserted-by":"publisher","first-page":"l1570","DOI":"10.1136\/bmj.l1570","volume":"365","author":"C Miles","year":"2019","unstructured":"Miles\u00a0C, Fanton\u00a0Z, Tome\u00a0M, Behr\u00a0ER. Inherited cardiomyopathies. BMJ. 2019;365:l1570.","journal-title":"BMJ"},{"key":"1776_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41569-020-0428-2","volume":"18","author":"WJ McKenna","year":"2021","unstructured":"McKenna\u00a0WJ, Judge\u00a0DP. Epidemiology of the inherited cardiomyopathies. Nat Rev Cardiol. 2021;18:22\u201336.","journal-title":"Nat Rev Cardiol"},{"key":"1776_CR3","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jacc.2021.12.002","volume":"79","author":"BJ Maron","year":"2022","unstructured":"Maron\u00a0BJ, Desai\u00a0MY, Nishimura\u00a0RA, et\u00a0al. Diagnosis and evaluation of hypertrophic cardiomyopathy. J\u00a0Am Coll Cardiol. 2022;79:372\u201389.","journal-title":"J Am Coll Cardiol"},{"key":"1776_CR4","first-page":"209","volume":"108","author":"C Prinz","year":"2011","unstructured":"Prinz\u00a0C, Farr\u00a0M, Hering\u00a0D, Horstkotte\u00a0D, Faber\u00a0L. The diagnosis and treatment of hypertrophic cardiomyopathy. Dtsch Arztebl Int. 2011;108:209\u201315.","journal-title":"Dtsch Arztebl Int"},{"key":"1776_CR5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1136\/heart.83.6.645","volume":"83","author":"A Steptoe","year":"2000","unstructured":"Steptoe\u00a0A, Mohabir\u00a0A, Mahon\u00a0NG, McKenna\u00a0WJ. Health related quality of life and psychological wellbeing in patients with dilated cardiomyopathy. Heart. 2000;83:645\u201350.","journal-title":"Heart"},{"key":"1776_CR6","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2165\/11588380-000000000-00000","volume":"29","author":"A Larg","year":"2011","unstructured":"Larg\u00a0A, Moss\u00a0JR. Cost-of-illness studies: a\u00a0guide to critical evaluation. PharmacoEconomics. 2011;29:653\u201371.","journal-title":"PharmacoEconomics"},{"key":"1776_CR7","volume-title":"Methods for the economic evaluation of health care programmes","author":"M Drummond","year":"2015","unstructured":"Drummond\u00a0M, Sculpher\u00a0MJ, Claxton\u00a0K, et\u00a0al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015."},{"key":"1776_CR8","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s40273-020-00952-0","volume":"38","author":"M Urbich","year":"2020","unstructured":"Urbich\u00a0M, Globe\u00a0G, Pantiri\u00a0K, et\u00a0al. A systematic review of medical costs associated with heart failure in the USA (2014\u20132020). PharmacoEconomics. 2020;38:1219\u201336.","journal-title":"PharmacoEconomics"},{"key":"1776_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta18560","volume":"18","author":"JL Colquitt","year":"2014","unstructured":"Colquitt\u00a0JL, Mendes\u00a0D, Clegg\u00a0AJ, et\u00a0al. Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation. Health Technol Assess. 2014;18:1\u2013560.","journal-title":"Health Technol Assess"},{"key":"1776_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s40258-013-0069-2","volume":"12","author":"F Gialama","year":"2014","unstructured":"Gialama\u00a0F, Prezerakos\u00a0P, Maniadakis\u00a0N. The cost effectiveness of implantable cardioverter defibrillators: a\u00a0systematic review of economic evaluations. Appl Health Econ Health Policy. 2014;12:41\u20139.","journal-title":"Appl Health Econ Health Policy"},{"key":"1776_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta18590","volume":"18","author":"F Campbell","year":"2014","unstructured":"Campbell\u00a0F, Thokala\u00a0P, Uttley\u00a0LC, et al. Systematic review and modelling of the cost-effectiveness of cardiac magnetic resonance imaging compared with current existing testing pathways in ischaemic cardiomyopathy. Health Technol Assess. 2014;18:1\u2013120.","journal-title":"Health Technol Assess"},{"key":"1776_CR12","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jval.2021.01.002","volume":"24","author":"OSJ Mandrik","year":"2021","unstructured":"Mandrik\u00a0OSJ, Bardach\u00a0A, Ghabri\u00a0S, et al. Critical appraisal of systematic reviews with costs and cost-effectiveness outcomes: an ISPOR Good Practices Task Force Report. Value Health. 2021;24:463\u201372.","journal-title":"Value Health"},{"key":"1776_CR13","unstructured":"Dutch CardioVascular Alliance. Double Dose. 2021. https:\/\/dcvalliance.nl\/our-consortia\/double-dose. Accessed 8 July 2021."},{"key":"1776_CR14","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1080\/14737167.2016.1246960","volume":"16","author":"GA van Mastrigt","year":"2016","unstructured":"van Mastrigt\u00a0GA, Hiligsmann\u00a0M, Arts\u00a0JJ, et al. How to prepare a\u00a0systematic review of economic evaluations for informing evidence-based healthcare decisions: a\u00a0five-step approach (part 1\/3). Expert Rev Pharmacoecon Outcomes Res. 2016;16:689\u2013704.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1776_CR15","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1080\/14737167.2016.1246962","volume":"16","author":"FW Thielen","year":"2016","unstructured":"Thielen\u00a0FW, Van Mastrigt\u00a0G, Burgers\u00a0LT, et\u00a0al. How to prepare a\u00a0systematic review of economic evaluations for clinical practice guidelines: database selection and search strategy development (part 2\/3). Expert Rev Pharmacoecon Outcomes Res. 2016;16:705\u201321.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1776_CR16","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/14737167.2016.1246961","volume":"16","author":"B Wijnen","year":"2016","unstructured":"Wijnen\u00a0B, Van Mastrigt\u00a0G, Redekop\u00a0WK, Majoie\u00a0H, De Kinderen\u00a0R, Evers\u00a0S. How to prepare a\u00a0systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, risk of bias, and transferability (part 3\/3). Expert Rev Pharmacoecon Outcomes Res. 2016;16:723\u201332.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1776_CR17","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page\u00a0MJ, McKenzie\u00a0JE, Bossuyt\u00a0PM, et\u00a0al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1776_CR18","unstructured":"International prospective register of systematic reviews. 2021. https:\/\/www.crd.york.ac.uk\/PROSPERO\/. Accessed 8 July 2021."},{"key":"1776_CR19","unstructured":"World Bank. The world by income. 2018. https:\/\/datatopics.worldbank.org\/world-development-indicators\/images\/figures-png\/world-by-income-sdg-atlas-2018.pdf. Accessed 8 July 2021."},{"key":"1776_CR20","unstructured":"Canadian Agency for Drugs and Technologies in Health. Strings attached: CADTH\u2019s database search filters. 2019. https:\/\/www.cadth.ca\/resources\/finding-evidence\/strings-attached-cadths-database-search-filters#health. Accessed 8 July 2021."},{"key":"1776_CR21","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1017\/S0266462309990523","volume":"25","author":"J Glanville","year":"2009","unstructured":"Glanville\u00a0J, Kaunelis\u00a0D, Mensinkai\u00a0S. How well do search filters perform in identifying economic evaluations in MEDLINE and EMBASE. Int J Technol Assess Health Care. 2009;25:522\u20139.","journal-title":"Int J Technol Assess Health Care"},{"key":"1776_CR22","unstructured":"Evidence for Policy and Practice Information and Coordinating Centre. CCEMG\u2014EPPI-centre cost converter. 2019. http:\/\/eppi.ioe.ac.uk\/costconversion\/default.aspx. Accessed 8 July 2021."},{"key":"1776_CR23","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1017\/S0266462305050324","volume":"21","author":"S Evers","year":"2005","unstructured":"Evers\u00a0S, Goossens\u00a0M, de Vet\u00a0H, van Tulder\u00a0M, Ament\u00a0A. Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria. Int J Technol Assess Health Care. 2005;21:240\u20135.","journal-title":"Int J Technol Assess Health Care"},{"key":"1776_CR24","doi-asserted-by":"publisher","first-page":"e13975","DOI":"10.1111\/petr.13975","volume":"25","author":"ALV Avance\u00f1a","year":"2021","unstructured":"Avance\u00f1a\u00a0ALV, Hutton\u00a0DW, Lee\u00a0J, Schumacher\u00a0KR, Si\u00a0MS, Peng\u00a0DM. Cost-effectiveness of implantable ventricular assist devices in older children with stable, inotrope-dependent dilated cardiomyopathy. Pediatr Transplant. 2021;25:e13975.","journal-title":"Pediatr Transplant"},{"key":"1776_CR25","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1038\/s41436-019-0582-2","volume":"21","author":"M Catchpool","year":"2019","unstructured":"Catchpool\u00a0M, Ramchand\u00a0J, Martyn\u00a0M, et al. A cost-effectiveness model of genetic testing and periodical clinical screening for the evaluation of families with dilated cardiomyopathy. Genet Med. 2019;21:2815\u201322.","journal-title":"Genet Med"},{"key":"1776_CR26","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.hrthm.2019.08.028","volume":"17","author":"PD Evers","year":"2020","unstructured":"Evers\u00a0PD, Anderson\u00a0JB, Ryan\u00a0TD, Czosek\u00a0RJ, Knilans\u00a0TK, Spar\u00a0DS. Wearable cardioverter-defibrillators in pediatric cardiomyopathy: a cost-utility analysis. Heart Rhythm. 2020;17:287\u201393.","journal-title":"Heart Rhythm"},{"key":"1776_CR27","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.cardfail.2010.04.009","volume":"16","author":"B Feingold","year":"2010","unstructured":"Feingold\u00a0B, Arora\u00a0G, Webber\u00a0SA, Smith\u00a0KJ. Cost-effectiveness of implantable cardioverter-defibrillators in children with dilated cardiomyopathy. J\u00a0Card Fail. 2010;16:734\u201341.","journal-title":"J Card Fail"},{"key":"1776_CR28","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.hrthm.2020.03.018","volume":"17","author":"MB Haag","year":"2020","unstructured":"Haag\u00a0MB, Hersh\u00a0AR, Toffey\u00a0DE, et al. Cost-effectiveness of in-home automated external defibrillators for children with cardiac conditions associated with risk of sudden cardiac death. Heart Rhythm. 2020;17:1328\u201334.","journal-title":"Heart Rhythm"},{"key":"1776_CR29","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1007\/s00246-020-02395-y","volume":"41","author":"MB Haag","year":"2020","unstructured":"Haag\u00a0MB, Hersh\u00a0AR, Toffey\u00a0DE, et al. Cost-effectiveness of implantable cardioverter-defibrillators in children with cardiac conditions associated with risk for sudden cardiac death. Pediatr Cardiol. 2020;41:1484\u201391.","journal-title":"Pediatr Cardiol"},{"key":"1776_CR30","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1136\/heartjnl-2011-300368","volume":"98","author":"J Ingles","year":"2012","unstructured":"Ingles\u00a0J, McGaughran\u00a0J, Scuffham\u00a0PA, Atherton\u00a0J, Semsarian\u00a0C. A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy. Heart. 2012;98:625\u201330.","journal-title":"Heart"},{"key":"1776_CR31","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ijcard.2020.02.055","volume":"311","author":"P Magnusson","year":"2020","unstructured":"Magnusson\u00a0P, Wimo\u00a0A. Health economic evaluation of implantable cardioverter defibrillators in hypertrophic cardiomyopathy in adults. Int J Cardiol. 2020;311:46\u201351.","journal-title":"Int J Cardiol"},{"key":"1776_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10047-015-0858-5","volume":"19","author":"T Takura","year":"2016","unstructured":"Takura\u00a0T, Kyo\u00a0S, Ono\u00a0M, et\u00a0al. Preliminary report on the cost effectiveness of ventricular assist devices. J\u00a0Artif Organs. 2016;19:37\u201343.","journal-title":"J Artif Organs"},{"key":"1776_CR33","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/eurheartj\/ehq067","volume":"31","author":"S Wordsworth","year":"2010","unstructured":"Wordsworth\u00a0S, Leal\u00a0J, Blair\u00a0E, et al. DNA testing for hypertrophic cardiomyopathy: a\u00a0cost-effectiveness model. Eur Heart\u00a0J. 2010;31:926\u201335.","journal-title":"Eur Heart J"},{"key":"1776_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/ejhg.2016.155","volume":"25","author":"K Nieuwhof","year":"2017","unstructured":"Nieuwhof\u00a0K, Birnie\u00a0E, Van Den Berg\u00a0MP, et al. Follow-up care by a\u00a0genetic counsellor for relatives at risk for cardiomyopathies is cost-saving and well-appreciated: A randomised comparison. Eur J Hum Genet. 2017;25:169\u201375.","journal-title":"Eur J Hum Genet"},{"key":"1776_CR35","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.amjcard.2016.04.059","volume":"117","author":"A Jan","year":"2016","unstructured":"Jan\u00a0A, Shah\u00a0MA, Rehman\u00a0S. Hypertrophic obstructive cardiomyopathy and the cost of treatment. Am J Cardiol. 2016;117:S4.","journal-title":"Am J Cardiol"},{"key":"1776_CR36","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/joa3.12215","volume":"35","author":"B Tripathi","year":"2019","unstructured":"Tripathi\u00a0B, Khan\u00a0S, Arora\u00a0S, et\u00a0al. Burden and trends of arrhythmias in hypertrophic cardiomyopathy and its impact of mortality and resource utilization. J\u00a0Arrhythm. 2019;35:612\u201325.","journal-title":"J Arrhythm"},{"key":"1776_CR37","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/joic.12319","volume":"29","author":"A Chothani","year":"2016","unstructured":"Chothani\u00a0A, Panaich\u00a0SS, Patel\u00a0N, et\u00a0al. Septal ablation and hypertrophic obstructive cardiomyopathy: 7\u00a0years US experience. J\u00a0Interv Cardiol. 2016;29:505\u201312.","journal-title":"J Interv Cardiol"},{"key":"1776_CR38","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.amjcard.2014.07.075","volume":"114","author":"SS Panaich","year":"2014","unstructured":"Panaich\u00a0SS, Badheka\u00a0AO, Chothani\u00a0A, et\u00a0al. Results of ventricular septal myectomy and hypertrophic cardiomyopathy (from Nationwide Inpatient Sample 1998\u20132010). Am J Cardiol. 2014;114:1390\u20135.","journal-title":"Am J Cardiol"},{"key":"1776_CR39","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1016\/j.athoracsur.2008.07.022","volume":"86","author":"WT Mahle","year":"2008","unstructured":"Mahle\u00a0WT, Ianucci\u00a0G, Vincent\u00a0RN, Kanter\u00a0KR. Costs associated with ventricular assist device use in children. Ann Thorac Surg. 2008;86:1592\u20137.","journal-title":"Ann Thorac Surg"},{"key":"1776_CR40","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1161\/CIRCULATIONAHA.112.000194","volume":"127","author":"AC Alba","year":"2013","unstructured":"Alba\u00a0AC, Alba\u00a0LF, Delgado\u00a0DH, Rao\u00a0V, Ross\u00a0HJ, Goeree\u00a0R. Cost-effectiveness of ventricular assist device therapy as a\u00a0bridge to transplantation compared with nonbridged cardiac recipients. Circulation. 2013;127:2424\u201335.","journal-title":"Circulation"},{"key":"1776_CR41","doi-asserted-by":"publisher","first-page":"276","DOI":"10.7326\/0003-4819-152-5-201003020-00005","volume":"152","author":"MT Wheeler","year":"2010","unstructured":"Wheeler\u00a0MT, Heidenreich\u00a0PA, Froelicher\u00a0VF, Hlatky\u00a0MA, Ashley\u00a0EA. Cost-effectiveness of preparticipation screening for prevention of sudden cardiac death in young athletes. Ann Intern Med. 2010;152:276\u2013W91.","journal-title":"Ann Intern Med"},{"key":"1776_CR42","doi-asserted-by":"publisher","first-page":"E380","DOI":"10.1542\/peds.2011-3241","volume":"130","author":"M Schoenbaum","year":"2012","unstructured":"Schoenbaum\u00a0M, Denchev\u00a0P, Vitiello\u00a0B, Kaltman\u00a0JR. Economic evaluation of strategies to reduce sudden cardiac death in young athletes. Pediatrics. 2012;130:E380\u2013E9.","journal-title":"Pediatrics"},{"key":"1776_CR43","doi-asserted-by":"publisher","first-page":"265","DOI":"10.4085\/1062-6050-45.3.265","volume":"45","author":"DP O\u2019Connor","year":"2010","unstructured":"O\u2019Connor\u00a0DP, Knoblauch\u00a0MA. Electrocardiogram testing during athletic preparticipation physical examinations. J\u00a0Athl Train. 2010;45:265\u201372.","journal-title":"J Athl Train"},{"key":"1776_CR44","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1161\/CIRCULATIONAHA.111.087940","volume":"125","author":"LK Leslie","year":"2012","unstructured":"Leslie\u00a0LK, Cohen\u00a0JT, Newburger\u00a0JW, et\u00a0al. Costs and benefits of targeted screening for causes of sudden cardiac death in children and adolescents. Circulation. 2012;125:2621\u20139.","journal-title":"Circulation"},{"key":"1776_CR45","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00246-013-0779-0","volume":"35","author":"BR Anderson","year":"2014","unstructured":"Anderson\u00a0BR, McElligott\u00a0S, Polsky\u00a0D, Vetter\u00a0VL. Electrocardiographic screening for hypertrophic cardiomyopathy and long QT syndrome: the drivers of cost-effectiveness for the prevention of sudden cardiac death. Pediatr Cardiol. 2014;35:323\u201331.","journal-title":"Pediatr Cardiol"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-023-01776-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12471-023-01776-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-023-01776-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T13:28:03Z","timestamp":1684243683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12471-023-01776-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1776"],"URL":"https:\/\/doi.org\/10.1007\/s12471-023-01776-1","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]},"assertion":[{"value":"3 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.\u00a0Wiethoff, B.\u00a0Goversen, M.\u00a0Michels, J.\u00a0van der Velden, M.\u00a0Hiligsmann, T.\u00a0Kugener and S.\u00a0M.\u00a0A.\u00a0A. Evers declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}